Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact

American Journal of Clinical Pathology

Volumn 137, Issue 6, 2012, Pages 946-956

  Sterlacci, William ^a   Savic, Spasenija ^b   Schmid, Thomas ^a   Oberaigner, Wilhelm ^a   Auberger, Jutta ^d   Fiegl, Michael ^c   Tzankov, Alexandar ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d St Johanns Spital   (Austria)

Author keywords

American thoracic society; Classification; European respiratory society; Histology; International association for the study of lung cancer; Non small cell lung cancer

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; MUCIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; DNA BINDING PROTEIN; KRT5 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TTF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE MICROARRAY; ADENOCARCINOMA; BIOPSY; CANCER STAGING; CLASSIFICATION; COHORT ANALYSIS; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; KERATIN-5; KERATIN-6; KERATIN-7; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84860765970     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP77KMKJXNMPMS     Document Type: Article

References (46)

1. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest. 2003;123(1 suppl):115S-128S. (Pubitemid 36135709)
2. Johnston WW. Percutaneous fine needle aspiration biopsy of the lung: a study of 1,015 patients. Acta Cytol. 1984;28:218-224. (Pubitemid 14110563)
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non - small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
4. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non - small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non - small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191. (Pubitemid 41095154)
7. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non - small cell lung cancer. Oncologist. 2007;12:713-718. (Pubitemid 47036205)
8. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8:15-27.
9. Rosell R, Moran T, Queralt C, et al; for the Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non - small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
11. Langer CJ. Roles of EGFR and KRAS mutations in the treatment of patients with non - small-cell lung cancer. P T. 2011;36:263-279.
12. Shah PL, Singh S, Bower M, et al. The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol. 2006;1:324-327. (Pubitemid 47163985)
13. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non - small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
14. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34:1805-1811.
15. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5:442-447.
16. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24:1348-1359.
17. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol. 2011;6:1190-1199.
18. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
19. Sterlacci W, Tzankov A, Veits L, et al. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. Am J Clin Pathol. 2011;135:611-618.
20. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34:1155-1162.
21. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653-664.
22. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23:273-279.
23. Travis W, Brambilla E, Müller-Hermelink H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
24. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-1068. (Pubitemid 34092881)
25. Sterlacci W, Fiegl M, Hilbe W, et al. Clinical relevance of neuroendocrine differentiation in non - small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch. 2009;455:125-132.
26. Hilbe W, Aigner K, Dittrich C, et al. Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms [in German]. Wien Klin Wochenschr. 2007;119:259-266. (Pubitemid 46895797)
27. Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis of lung cancer: the TYROL study: daily routine in 1,424 patients (1995-2006) [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 19063.
28. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18:142-149.
29. La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457:497-507.
30. Sterlacci W, Wolf D, Savic S, et al. High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer [published online ahead of print August 15, 2011]. Hum Pathol. 2012;43:339-349. doi:10.1016/j. humpath.2011.05.017.
31. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non - small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-218.
32. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12:240-247.
33. Jorda M, Gomez-Fernandez C, Garcia M, et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer. 2009;117:46-50.
34. Khayyata S, Yun S, Pasha T, et al. Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37:178-183.
35. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36:20-25.
36. Camilo R, Capelozzi VL, Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non - small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
37. Downey P, Cummins R, Moran M, et al. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS. 2008;116:526-529.
38. Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15-19. (Pubitemid 44415395)
39. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
40. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16. (Pubitemid 30055417)
41. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772. (Pubitemid 40685594)
42. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
43. Mukhopadhyay S, Katzenstein AL. Subclassification of non - small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.
44. Yanagita E, Imagawa N, Ohbayashi C, et al. Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl Immunohistochem Mol Morphol. 2011;19:509-513.
45. Fatima N, Cohen C, Lawson D, et al. TTF-1 and napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol. 2011;119:127-133.
46. Pelosi G, Fabbri A, Bianchi F, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non - small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012;7:281-290. doi:10.1097/JTO.0b013e31823815d3.